The introspection on the diagnosis and treatment process of a case of Guillain–Barré syndrome (GBS) attributed to systemic lupus erythematosus (SLE)

A case report

Nan Zhang, MSa,b, Jie Cao, MDa, Meng Zhao, MSa, Li Sun, MD*a

Abstract

Rationale: Systemic lupus erythematosus (SLE) is an autoimmune inflammatory connective tissue disorder. It may cause neurologic damage which is mainly characterized by central and mental system, while peripheral sexual damage is relatively rare in which Guillain–Barré Syndrome (GBS) as the first performance is more rare. GBS is an autoimmune peripheral neuropathy usually triggered by an antecedent bacterial or viral infection, with SLE being a rare cause.

Patient concerns: A 65-year-old male presented to the hospital with progressive numbness and adynamia in extremities. His vital signs were stable. 5 days later, his condition aggravated and mechanical ventilation was necessitated owing to severe dyspnea.

Diagnoses: Based on the clinical symptoms and results of the lumbar puncture and electromyography, he was first diagnosed as GBS; however, after treatment his condition was deteriorate and the blood test showed abnormal immune indices, then renal biopsy was performed, which confirmed the diagnosis of peripheral nervous system in patients with systemic lupus erythematosus (PNS-SLE).

Interventions: Firstly he was treated with intravenous immunoglobulin (IVIG) for 5 days. After his condition deterioration, he was conducted endotracheal intubation and, finally, a tracheostomy was performed. Later on he was treated with steroid therapy for several weeks.

Outcomes: The patient showed remarkable recovery and was able to walk on his own by the time of discharge.

Lessons: PNS-SLE can, by itself, be one of the main causes of morbidity and mortality. Electromyography and renal biopsy should be considered when relevant. Peripheral neuropathy in SLE should be given greater recognition, and rarer forms of presentation should be taken seriously in the differential diagnosis when the clinical picture is atypical. Glucocorticoids may play an important role in the treatment of PNS-SLE.

Abbreviations: CSF = examination of the cerebrospinal fluid, EMG = electromyography, GBS = Guillain–Barré Syndrome, IVG = intravenous immunoglobulin, NP = neuropsychiatric, NPSLE = neuropsychiatric systemic lupus erythematosus, PNS-SLE = peripheral nervous system in patients with systemic lupus erythematosus, SLE = systemic lupus erythematosus.

Keywords: Guillain–Barré syndrome, intravenous immunoglobulin, neuropsychiatric systemic lupus erythematosus, peripheral nervous system in patients with systemic lupus erythematosus, steroid therapy

1. Introduction

Neuropsychiatric systemic lupus erythematosus (NPSLE) includes 19 neuropsychiatric (NP) syndromes from which 12 involve the central nervous system and 7 the peripheral nervous system (PNS).

Editor: N/A.

The authors have no funding and conflicts of interest to disclose.

* Department of Neurology and Neuroscience Center, the First Hospital of Jilin University, Changchun, Jilin. † Department of Neurology, Yizhu Central Hospital, Weifang, Shandong, China.

Correspondence: Li Sun, Department of Neurology, the First Hospital of Jilin University, 71 Xinmin Street, Changchun 130021, China (e-mail: sjnksunli@163.com).

Received: 24 August 2017 / Received in final form: 9 November 2017 / Accepted: 10 November 2017

https://doi.org/10.1097/MD.0000000000009037

seen in patients with systemic lupus erythematosus (SLE) in which other causes have been excluded.[1] These symptoms may precede the onset of SLE or may occur at any time during the course of SLE[2–3] in which is not only in the setting of active SLE but also during quiescent.[1] The PNS involvement occurs more frequently in patients who are diagnosed with SLE at older age than those without PNS involvement.[4–5] The prevalence of PNS involvement occurs in 1.5% to 17.7% of patients and over half of them attribute to SLE.[4–9] The most common PN-related symptoms were myasthenia and numbness in affected regions.[1] Its most frequent manifestation is sensory-motor axonal polyneuropathy.[6–8] Conversely, the prevalence of Guillain–Barré syndrome (GBS) is very low in all series.[6–9,12–13] GBS is an autoimmune peripheral neuropathy usually triggered by an antecedent bacterial or viral infection. The disease is characterized by a rapidly progressive, symmetrical, and ascending motor paralysis with hypotonia and areflexia. Examination of the cerebrospinal fluid (CSF) demonstrates albuminocytologic dissociation; electrophysiological parameters, such as nerve conduction velocity, H-reflexes, and F waves, indicate sensory-motor demyelinating polyneuropathy. GBS which is also classified under the peripheral involvement in
which other causes have been excluded has been rarely associated with SLE.[1] Disorders of peripheral nervous system in patients with systemic lupus erythematosus (PN-SLE) are a major cause of morbidity.[2] Nervous system involvement in patients with SLE manifests as a nonspecific heterogeneous group of NP symptoms.[3] Currently, there are no known laboratory or radiological biomarkers of NPSLE. Moreover, clinical guidance for diagnosis and therapeutic decision making in these patients is not available.[4] In clinical practice, multidisciplinary diagnostic and therapeutic approach is recommended in these patients based on the suspected cause and the severity of symptoms.[5] NPSLE is typically diagnosed when the patient is symptomatic (based on patient complaints or the physician’s assessment).[6] Due to the lack of a gold standard, the attribution of NPSLE represents a clinical challenge; diagnosis is largely based on exclusion of other potential causes. NP events in patients with SLE have a detrimental effect on the quality of life and are associated with a poor prognosis.[7] Here, we report a case of GBS associated with SLE and according to the neurological manifestations, renal biopsy and SLE serology confirm the diagnosis of PNS-SLE, which was seldom seen. At the beginning, after treatment with intravenous immunoglobulin (IVIG), his symptoms did not improve and the patient remained dependent on mechanical ventilation. Partial recovery was only achieved after several weeks of steroid therapy.

2. Case presentation

The study was approved by the ethical committee of First Hospital of Jilin University, China. Written informed consent was obtained the individual participant included in the study.

3. Patient

A 65-year-old man from Changchun, China presented to the emergency department at the First Hospital of Jilin University on August 21, 2013, with progressive numbness and adynamia in his extremities. Approximately 2 weeks prior to hospitalization, the patient had suffered from fever and low back pain. Nine days prior to admission, he experienced dizziness and had headache accompanied by aggravation of numbness and weakness in all extremities, and inability to cough. A lumbar puncture yielded clear CSF; CSF examination showed WBC count of 3.0 x 10^3/μL with a predominance of monocytes; protein concentration was 1.77 g/L (albuminocytologic dissociation); and glucose concentration was 3.60 mmol/L. The CSF results were not consistent with a diagnosis of GBS. Electromyography (EMG) study of the median, ulnar, peroneal, and tribal nerves revealed gross reduction in motor nerve conduction velocity.

4. Physical examination and laboratory tests

At admission, his vital signs were stable; he had no dyspnea, and his oxygen saturation was 98% (room air). Systemic examination was unremarkable. There was no edema in the lower extremities. The patient was conscious, coherent, and well oriented. He was able to fully comprehend his condition and surroundings, and his speech remained fluent.

Results of tests on the cranial nerve were normal; however, he experienced diplopia and the right nasal groove was shallow. The muscles in all 4 limbs were hypotonic. On a scale of 1 to 5, the muscle power in the upper extremities was grade 4 and in the lower extremities, grades 2 to 3. Superficial reflexes were normal; there were no deep-tendon jerks but there were ataxia. There was hypoalgesia of hands and distal lower limb from approximately 10 cm below the knee joint.

Laboratory findings on admission included normal complete blood counts (white blood cells [WBCs], 6.44 x 10^9/L; red blood cells, [RBCs] 4.38 x 10^12/L; and hemoglobin, 130 g/L). Renal function test results were within normal limits (blood urea nitrogen [BUN], 5.81 mmol/L; creatinine, 69.7 μmol/L). With the exception of serum potassium (4.0 mmol/L), his serum electrolyte levels were abnormal (serum sodium, 124.0 mmol/L; serum chloride, 90.9 mmol/L). Vitamin B12 level was elevated at 1107 pmol/L. Erythrocyte sedimentation rate and high-sensitivity C-reactive protein were elevated (67.0 mm/hour and 14.4 mg/mL, respectively).

High immunoglobulin G (22.7 g/L) and low complement 3 (C3) (0.79 g/L) were observed. Serum HCV antibody was positive and the HCV RNA detected using fluorescent quantitative polymerase chain reaction showed values above the normal range (2.8 E7 IU/mL < 1.0 E3). Rapid HIV test was nonreactive.

Routine urine test showed proteinuria and RBC and cast counts of 628.40 and 0.84 μL, respectively. Computed tomography scan of the head showed no signs of intracranial hemorrhage, mass, or other intracranial pathology. Magnetic resonance imaging of the brain and spinal cord was unremarkable.

Following the initial workup, the patient was diagnosed with GBs, and a trial of IVIG at 0.4 g/kg/day was given for a period of 5 days. Approximately 3 days after the start of treatment, the patient experienced difficulty in falling asleep accompanied by aggravation of numbness and weakness in the extremities, and inability to cough. A lumbar puncture yielded clear CSF; CSF examination showed WBC count of 3.0 x 10^3/μL with a predominance of monocytes; protein concentration was 1.77 g/L (albuminocytologic dissociation); and glucose concentration was 3.60 mmol/L. The CSF results were not consistent with a diagnosis of GBS.

Electromyography (EMG) study of the median, ulnar, peroneal, and tribal nerves revealed gross reduction in motor nerve conduction velocity; distal latency was grossly prolonged in all nerves, while F waves were absent in all the nerves. H-reflexes were absent on both sides, and sensory nerve action potential was absent in the ulnar nerves (Tables 1–3).

| Nerve   | Latency, ms | Amplitude, mv | Conduction velocity, m/s | F wave |
|---------|-------------|---------------|--------------------------|--------|
| Ulnar   | 3.19*       | 2.9/2.4      | 43.9/41.9                | –      |
| Median  | 7.00*       | 2.3/2.0      | 37.9                    | –      |
| Tribal  | 6.44*       | 3.8/2.3      | 38.7                    | –      |
| Peroneal| 5.36*       | 4.71         | 37.61                   | –      |

The median, ulnar, peroneal, and tribal nerves revealed gross reduction in motor nerve conduction velocity; distal latency was grossly prolonged in all nerves. F waves were absent in all the nerves.
After IVIG treatment, the weakness progressed (muscle power in the upper extremities was grade 3 and that in the lower extremities was at grade 2) and the patient had difficulty swallowing, coughing, and breathing. We then conducted endotracheal intubation and, finally, a tracheostomy was performed.

Taking into consideration the patient’s history of rheumatism, tests for immune indices were performed; the results were as follows: anti-ds-DNA positive titer: 1:10; homogeneous pattern positive titer: 1:1000; and cytoplasmic particle type positive titer: 1:1000. anti-SSA, anti-SSB, anti-Sm, anti-Nrnp/Sm, and anti-Jo-1 were negative. Based on these results, SLE was suspected. Renal biopsy (Fig. 1) showed focal glomerulonephritis and positive IgA, IgM, C1q, and C3, which confirmed the diagnosis of SLE.

Considering the patient’s condition and the diagnosis of SLE, we opted for a trial of steroid therapy. The patient showed a remarkable response to 2 weeks of aggressive therapy and began to recover. We were able to withdraw the artificial breathing apparatus, and the patient was able to take a few steps by himself upon discharge.

5. Discussion

PNS-SLE is one of the main causes of morbidity and mortality.[17] There are 7 types of peripheral neuropathy associated with SLE in which includes acute inflammatory demyelinating polyradiculoneuropathy, autonomic disorder, mononeuropathy, myasthenia gravis, neuropathy, plexopathy, and polyneuropathy. The most common type of PNS-SLE was polyneuropathy with sensory involvement, followed by mononeuropathy. GBS associated with SLE is relatively rare. The prevalence of peripheral neuropathies associated with SLE is variable (range 1.5%–17.7%) and about 60% attributable to SLE.[18–9] In nearly half of them, PNS-SLE involvement was the only manifestation of the SLE flare when it appeared.[9] The pathogenesis is unclear, although it has been linked to vascular disease of the small arteries that supply the affected nerves.[20,21] GBS is a heterogeneous condition with several variant forms. This acute monophasic progressive disease presents with symmetrical muscle weakness and absent or attenuated deep-tendon reflexes.

GBS is a rare manifestation of SLE, which falls under the category of PNS-SLE.[15,22–25] GBS, as the initial presentation of SLE, has been reported in only a few cases to this day.[15,22] The exact pathophysiology of this relationship is largely unknown; however, cross-reactivity between the auto-antibodies associated with SLE and those formed against myelin tissue is believed to be involved.[26] In addition, immune-suppression associated with SLE is an aggravating factor which exacerbates the neuronal inflammation in these patients.[22,27] The older people were more likely to suffer from PNS-SLE than those without peripheral neuropathies.[4] Although there is no clear recommendation for the treatment of PNS-SLE, induction treatment with glucocorticoids with or without immunosuppressant agents are indicated if the PNS-SLE appears in the context of lupus activity.[27] Overall, global response (complete and/or partial) to treatments was achieved in 77.4% of patients in some studies without differences between the types of PNS-SLE involvement.[5,6] Our patient was also in the context of lupus activity and partial recovered with the treatment with glucocorticoids.

In our present report, we described a case of GBS associated with SLE which finally diagnosed as PNS-SLE. The clinical features, the results of the CSF, magnetic resonance imaging, and EMG supported the diagnosis and treated with IVIG at the beginning. However, he was not sensitive to the IVIG and the condition aggravated.

### Table 2

| Nerve   | Latency, ms | Amplitude, mv | Conduction velocity, m/s |
|---------|-------------|---------------|--------------------------|
| Ulnar   | 2.65        | 2.71          | 41.5†                    |
| Median  | 2.70        | 4.51†         | 48.1                     |
| Superficial | 2.09      | 10.1          | 52.6                     |
| Sural   | 1.62        | 5.7           | 61.7                     |

The median, ulnar nerves revealed reduction in sensory conduction velocity.

### Table 3

| Right tibial nerve H reflex. | M-Lat, ms | H-Lat, ms | H/M amp |
|-----------------------------|-----------|-----------|---------|
| Knee gastrocnemius muscle   | 6.4       | –         | –       |

H-reflexes were absent on both sides.

Figure 1. Histopathological examination of renal biopsy specimen showing focal lupus nephritis (ISN/PPS 2004 classification lupus nephritis).
as influenza or diarrhea but had a history of rheumatism and infected with HCV, moreover the serological examination of rheumatic immunity was positive, so we considered that the GBS might be attributed to SLE not other causes. Then the renal biopsy was conducted and finally confirmed our conjecture.

Our patient was initially diagnosed with GBS, which was confirmed by CSF analysis, EMG, and nerve-conduction studies, as well as by clinical observation. However, he had no history of infection and premonitory symptoms which excluded other causes and according to the renal biopsy, the diagnosis of PNS-SLE was confirmed. When the GBS patients lack definite history of infection, care should be taken not to overlook the possibility of connective tissue disease as the etiology of peripheral neuropathy, because it may easily be attributed to other causes. And this may also explain why after use the IVIG the symptoms of our patient did not improve. Because of the differences in pathogenesis and epidemiology, the treatment effect was different. Pulsed glucocorticoid therapy (eg, prednisone and methylprednisolone) is the treatment of choice for the management of SLE. Cyclophosphamide is yet another immunosuppressive agent used to control manifestations of SLE. Although, immune suppressants and interferon should be used to treat SLE and HCV, respectively, these may result in an increase in viral replication and the standard therapy with interferon might have neurological side effects, such as nerve palsy and peripheral neuropathy. After assessment the pros and cons, we did not use the immune suppressants and interferon. Luckily, he was picking up after using glucocorticoids.

Our experience with this patient showed that GBS might attribute to SLE. A high index of suspicion for SLE in such cases may help avoid any unnecessary delay in diagnosis and help improve prognosis of the patient.

Acknowledgments

The authors thank the Department of Pathology at the First Hospital of Jilin University for providing the results of the renal biopsy as well as to all clinicians who helped complete this study.

References

[1] The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599–608.
[2] Ward MM, Studenski S. The time course of acute psychiatric episodes in systemic lupus erythematosus. J Rheumatol 1991;18:1533–9.
[3] van Dam AP, Wekking EM, Callewaert JA, et al. Psychiatric symptoms before systemic lupus erythematosus is diagnosed. Rheumatol Int 1994;14:57–62.
[4] Oomata A, Fang H, Petri M, et al. Peripheral neuropathies in systemic lupus erythematosus: clinical features, disease associations, and immunologic characteristics evaluated over a twenty-five-year study period. Arthritis Rheumatol 2014;66:1000–9.
[5] Toledano P, Orueza R, Rodríguez-Pinto I, et al. Peripheral nervous system involvement in systemic lupus erythematosus: prevalence, clinical and immunological characteristics, treatment and outcome of a large cohort from a single centre. Autoimmun Rev 2017;16:750–5.
[6] Florica B, Aghdassi E, Su J, et al. Peripheral neuropathy in patients with systemic lupus erythematosus. Semin Arthritis Rheum 2011;41:203–11.
[7] Hanly JG, Urowitz MB, Sanchez-Guerrero J, et al. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum 2007;56:265–73.
[8] Hanly JG, Urowitz MB, Su L, et al. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2010;69:529–35.
[9] Hanly JG, Urowitz MB, Su L, et al. Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study. Arthritis Rheum 2008;59:721–9.
[10] Xianbin W, Mingyu W, Dong X, et al. Peripheral neuropathies due to systemic lupus erythematosus in China. Medicine (Baltimore) 2015;94:625.
[11] Ondal R, Loshet S, Torbergen T, et al. Peripheral neuropathy in systemic lupus erythematosus – a longitudinal study. Acta Neurol Scand 2001;103:386–91.
[12] Agarwal AK. Acute inflammatory polyneuropathy in systemic lupus erythematosus. JACM 2005;6:334–6.
[13] Brey RL, Holliday SL, Sklad AR, et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 2002;58:1214–20.
[14] Hantson P, Kever L, Fabien N, et al. Acute-onset chronic inflammatory demyelinating polyneuropathy with cranial nerve involvement, dysautonomia, respiratory failure, and autoantibodies. Muscle Nerve 2010;41:423–6.
[15] Hou TY, Wang SH, Kuo CF, et al. Acute inflammatory demyelinating polyneuropathy as the initial presentation of lupus. Am J Emerg Med 2009;27:990.e3-5.
[16] Jelisch-David H, Muller S. Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers. Nat Rev Neurol 2014;10:579–96.
[17] Magro-Checa C, Zirckee EJ, Huizenga TW, et al. Management of neuropsychiatric systemic lupus erythematosus: current approaches and future perspectives. Drugs 2016;76:459–83.
[18] Zirckee EJ, Steup-Beekman GM, van der Mast RC, et al. Prospective study of clinical phenotypes in neuropsychiatric systemic lupus erythematosus; multidisciplinary approach to diagnosis and therapy. J Rheumatol 2012;39:2118–26.
[19] Faria R, Goncalves J, Dias R. Neuropsychiatric systemic lupus erythematosus involvement: towards a tailored approach to our patients? Rambam Maimonides Med J 2017;8:e0001.
[20] Tao L, Huang P, Wang S, et al. Peripheral neuropathy as the initial presentation of lupus. J Clin Neurophysiol 2011;28:440–2.
[21] Popescu A, Kao AH. Neuropsychiatric systemic lupus erythematosus. Curr Neuropsychopharmacol 2011;9:449–57.
[22] Robson MG, Walport MJ, Davies KA. Systemic lupus erythematosus and acute demyelinating polyneuropathy. Br J Rheumatol 1994;33:1074–7.
[23] Vaida S, Jain HS, Logan J. Systemic lupus erythematosus and guillain-barre syndrome. J Clin Rheumatol 1999;5:349–53.
[24] Fazio RM, Chen I, Somal N. Guillain-Barre syndrome as first presentation of systemic lupus erythematosus: a rare manifestation complicated by IVIG-induced splenic infarct. BMJ Case Rep 2015;2015: doi:10.1136/bcr-2015-211598.
[25] Govoni M, Bortoluzi A, Padovan M, et al. The diagnosis and clinical management of the neuropsychiatric manifestations of lupus. J Autoimmun 2016;74:41–72.
[26] Niazi MA, Azhar A, Tufail K, et al. Guillain-Barre syndrome associated with peginterferon alfa-2a for chronic hepatitis C: a case report. World J Hepatol 2010;2:162–6.